Martina Jones

Martina Jones

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2016 in Scientific Reports
Verified
Journal Article
Open access
MJMartina Jones
Martina Jones
MAMohamed Alfaleh
Mohamed Alfaleh
SKSumukh Kumble
Sumukh Kumble
SZShuo Zhang
Shuo Zhang
GOGeoffrey W. Osborne
Geoffrey W. Osborne
SMStephen Mahler
Stephen Mahler
A critical factor in the successful isolation of new antibodies by phage display is the presentation of a correctly folded antigen. While this is relatively simple for soluble proteins which can be purified and immobilized onto a plastic surface, membrane proteins offer significant challenges for antibody discovery. Whole cell panning allows presentation of the membrane protein in its native conformation, but is complicated by a low target antigen density, high background of irrelevant antigens and non-specific binding of phage particles to cell surfaces. The method described here uses transient transfection of alternating host cell lines and stringent washing steps to address each of these limitations. The successful isolation of antibodies from a naive scFv library is described for three membrane bound proteins; human CD83, canine CD117 and bat CD11b.

1 January 2021 in Clinical & Translational Immunology
Verified
Journal Article
Open access
PDF file
DWDaniel Watterson
Daniel Watterson
DWDanushka K Wijesundara
Danushka K Wijesundara
NMNaphak Modhiran
Naphak Modhiran
FMFrancesca L Mordant
Francesca L Mordant
ZLZheyi Li
Zheyi Li
KCKeith J Chappell
Keith J Chappell
Objectives: Efforts to develop and deploy effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) continue at pace. Here, we describe rational antigen design through to manufacturability and vaccine efficacy of a prefusion‐stabilised spike (S) protein, Sclamp, in combination with the licensed adjuvant MF59 ‘MF59C.1’ (Seqirus, Parkville, Australia).Methods: A panel recombinant Sclamp proteins were produced in Chinese hamster ovary and screened in vitro to select a lead vaccine candidate. The structure of this antigen was determined by cryo‐electron microscopy and assessed in mouse immunogenicity studies, hamster challenge studies and safety and toxicology studies in rat.Results: In mice, the Sclamp vaccine elicits high levels of neutralising antibodies, as well as broadly reactive and polyfunctional S‐specific CD4+ and cytotoxic CD8+ T cells in vivo. In the Syrian hamster challenge model (n = 70), vaccination results in reduced viral load within the lung, protection from pulmonary disease and decreased viral shedding in daily throat swabs which correlated strongly with the neutralising antibody level.Conclusion: The SARS‐CoV‐2 Sclamp vaccine candidate is compatible with large‐scale commercial manufacture, stable at 2–8°C. When formulated with MF59 adjuvant, it elicits neutralising antibodies and T‐cell responses and provides protection in animal challenge models.

10 June 2016 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
CHChristopher B. Howard
Christopher B. Howard
NFNicholas Fletcher
Nicholas Fletcher
ZHZachary H. Houston
Zachary H. Houston
AFAdrian V. Fuchs
Adrian V. Fuchs
NBNathan R. B. Boase
Nathan R. B. Boase
Kris ThurechtKris Thurecht
Kris Thurecht

1 March 2010 in Journal of Immunological Methods
Verified
Journal Article
Closed access
MJMartina Jones
Martina Jones
TSTherese Seldon
Therese Seldon
MSMatthew Smede
Matthew Smede
ALAshleigh Linville
Ashleigh Linville
DCDavid Y. Chin
David Y. Chin
TMTrent P. Munro
Trent P. Munro

1 September 2002 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
MJMartina Jones
Martina Jones
PNPeter F. Nixon
Peter F. Nixon
The dietary supply of folates and their measurement are both affected, potentially, by the instability of some folates. Labile folates appear to be stabilized by binding to folate-binding protein (FBP); this paper reports measurements of that stabilization. The degradation rates of the very labile tetrahydrofolate (H4folate) and moderately labile 5-methyltetrahydrofolate (5-CH3H4folate) were measured with the compounds free or bound to either soluble or immobilized bovine milk FBP. Complexation increased stability from 2- to > 1000-fold, depending on buffer and temperature conditions. H4folate at 4°C and pH 6.7 appeared to be quite stable for > 100 d when bound to soluble FBP but had a half-life of < 1 h when free. Stabilization of milk folates may be a role of FBP and would improve the bioavailability of milk folate to newborns and other consumers.

5 August 2017 in Antibodies
Verified
Journal Article
Open access
PDF file
MAMohamed Alfaleh
Mohamed Alfaleh
MJMartina Jones
Martina Jones
CHChristopher B. Howard
Christopher B. Howard
SMStephen Mahler
Stephen Mahler
Membrane proteins are attractive targets for monoclonal antibody (mAb) discovery and development. Although several approved mAbs against membrane proteins have been isolated from phage antibody libraries, the process is challenging, as it requires the presentation of a correctly folded protein to screen the antibody library. Cell-based panning could represent the optimal method for antibody discovery against membrane proteins, since it allows for presentation in their natural conformation along with the appropriate post-translational modifications. Nevertheless, screening antibodies against a desired antigen, within a selected cell line, may be difficult due to the abundance of irrelevant organic molecules, which can potentially obscure the antigen of interest. This review will provide a comprehensive overview of the different cell-based phage panning strategies, with an emphasis placed on the optimisation of four critical panning conditions: cell surface antigen presentation, non-specific binding events, incubation time, and temperature and recovery of phage binders.